Last Posted: May 20, 2019
- Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review.
Wright Stuart J et al. PharmacoEconomics 2019 May - The costliest drug on the planet will treat infants with rare disease. The market fight focused on cost and safety is just getting started.
C Rowland, NY Times, May 15, 2019 - Cost-effectiveness of newborn screening for severe combined immunodeficiency.
Van der Ploeg Catharina P B et al. European journal of pediatrics 2019 May 178(5) 721-729 - Repurposing large health insurance claims data to estimate genetic and environmental contributions in 560 phenotypes.
Lakhani Chirag M et al. Nature genetics 2019 51(2) 327-334 - An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities.
Thiboonboon Kittiphong et al. PloS one 2018 13(6) e0199318 - Building Linked Big Data for Stroke in Korea: Linkage of Stroke Registry and National Health Insurance Claims Data.
Kim Tae Jung et al. Journal of Korean medical science 2018 Dec 33(53) e343 - Economic evaluation of genomic sequencing in the paediatric population: a critical review.
Alam Khurshid et al. European journal of human genetics : EJHG 2018 26(9) 1241-1247 - The Uniformed Services University's Surgical Critical Care Initiative (SC2i): Bringing Precision Medicine to the Critically Ill.
Belard Arnaud et al. Military medicine 2018 183(suppl_1) 487-495 - Bayesian Networks for Risk Prediction Using Real-World Data: A Tool for Precision Medicine.
Arora Paul et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Apr 22(4) 439-445 - A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine.
Fahr Patrick et al. Applied health economics and health policy 2019 Apr
No hay comentarios:
Publicar un comentario